COVID-19 and Cannabidiol (CBD).
| Autor: | Khalsa JH; US National Institute on Drug Abuse, NIH; Medical Consequences of Drug Abuse and Infections Branch, National Institute on Drug Abuse, NIH, Bethesda, Maryland (JHK); Samaritan Daytop Village Treatment Center and NYU Medical School, New York (GB); Microbiology, Immunology, and Tropical Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC (SBM); Institute of Human Virology University of Maryland School of Medicine, Baltimore, Maryland (SK)., Bunt G, Maggirwar SB, Kottilil S |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of addiction medicine [J Addict Med] 2021 Sep-Oct 01; Vol. 15 (5), pp. 355-356. |
| DOI: | 10.1097/ADM.0000000000000771 |
| Abstrakt: | COVID-19 pandemic has resulted in devastating mortality and morbidity consisting of socioeconomic and health effects that have included respiratory/pulmonary, cardiovascular, mental health and neurological consequences such as anxiety, depression, and substance use. Extensive efforts are underway to develop preventive vaccines and therapeutics such as remdesivir, dexamethasone, convalescent plasma, and others to treat COVID-19 but many report residual mental health problems after recovery. Cannabis products such as cannabidiol (CBD) are being advertised for the treatment of COVID-19 associated mental health problems and substance use disorders. This commentary will briefly clear the myth that CBD can ameliorate a wide range of COVID-19 associated health effects including anxiety, depression, or any substance use disorder, and show that there is a clear lack of sufficient unbiased clinical evidence from well-designed double-blind, placebo-controlled clinical trials to prove the antianxiety or antidepression therapeutic properties of CBD and support its wide use as medicine to treat COVID-19- associated mental health conditions or substance use disorders. Finally, we suggest that addiction physicians must play an important role in dealing with their patients requesting CBD prescription for treating any of these conditions. Competing Interests: Research grants to the institution from Merck, Inc., Gillead Sciences, and Airbutus pharmaceuticals. Other authors report no conflicts of interest. (Copyright © 2020 American Society of Addiction Medicine.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|